VEGF-targeted therapy: therapeutic potential and recent advances.
After over 30 years of theorizing, the use of angiogenesis inhibitors as anticancer therapy has finally moved from the realm of research to reality. Normal adult vasculature is generally quiescent in nature, with endothelial cells dividing approximately every 10 years. In contrast, the growth of tumors requires constant vascular growth and remodeling in order for solid tumors to grow beyond 1-2 mm(3) in size. Vascular endothelial growth factor (VEGF) and its receptors are key regulators of the process of angiogenesis, which makes them attractive therapeutic targets. A multitude of VEGF-targeted inhibitory agents are currently being investigated for the treatment of cancer. This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers.
Rosen
Lee S
LS
John Wayne Cancer Institute and St. John's Health Center, Santa Monica, California, USA. lrosen@premiereoncology.com
D020533:Angiogenesis Inhibitors / Q000145:classification / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D016503:Drug Delivery Systems; D004502:Education, Medical, Continuing; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D008495:Medical Oncology / Q000639:trends*; D042442:Vascular Endothelial Growth Factors / Q000187:drug effects*
D020533:Angiogenesis Inhibitors; D042442:Vascular Endothelial Growth Factors